| Expression pattern: |
UP |
| Associated gene: |
METTL3, YTHDC1, AKT1, PIK3CA, CDC25B, WEE1, CTNNB1, CDKN1A, AKT, ERK1 |
| Associated microRNA: |
- |
| Biological function: |
impairs cell cycle progression when depleted; affects proliferation-related pathways; causes accumulation of cells in G2 phase |
| Molecular mechanism: |
circVAMP3 depletion deregulates AKT-related genes/proteins (AKT1/AKT; ERK1; CTNNB1) and cell-cycle regulators (WEE1; CDKN1A), impacting G2/M checkpoint; circVAMP3 shows differential m6A pattern compared to linear VAMP3 |
| Biological pathway or process: |
PI3K/AKT (inhibits); ERK (inhibits); cell cycle (other); proliferation (inhibits); m6A modification (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; divergent primers PCR; Sanger Sequencing; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; Transfection; Western Blot; Cell Cycle Assay; Bioinformatics Analysis |
| Clinical significance: |
putative future therapeutic target |
| Description: |
circVAMP3 (hsa_circ_0006354) is up-regulated in the ARMS cell line RH4 and is mainly cytoplasmic. siRNA knockdown of circVAMP3 alters AKT/ERK-related signaling and cell-cycle regulators (e.g., WEE1, CDKN1A), leading to impaired cell-cycle progression with G2 accumulation, supporting circVAMP3 as a potential therapeutic target in alveolar rhabdomyosarcoma. |
| Confidence score: |
0.6862 |